ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1407-1413

  Iikura, Minami ^a   Furihata, Tomomi ^a   Mizuguchi, Misa ^a   Nagai, Miki ^a   Ikeda, Masanori ^b   Kato, Nobuyuki ^b   Tsubota, Akihito ^c   Chiba, Kan ^a  

^a CHIBA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; MESSENGER RNA; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG UPTAKE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CELL LINE, TUMOR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GENES, REPORTER; HEPACIVIRUS; HEPATOCYTES; HUMANS; LUCIFERASES; MICRORNAS; RIBAVIRIN; RNA, MESSENGER; THIOINOSINE;

EID: 84857172274     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05762-11     Document Type: Article

References (22)

1. Bachmakov I, Glaeser H, Fromm MF, König J. 2008. Interaction of oral antidiabetic drugs with hepatic uptake transporters: Focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes 57:1463-1469.
2. Becker ML, et al. 2009. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 9:242-247.
3. +- dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells. J. Pharmacol. Exp. Ther. 286:1333-1340.
4. Dixit NM, Perelson AS. 2006. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell. Mol. Life Sci. 63:832-842. (Pubitemid 43724073)
5. Fried MW, et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
6. Fukuchi Y, Furihata T, Hashizume M, Iikura M, Chiba K. 2010. Characterization of ribavirin uptake systems in human hepatocytes. J. Hepatol. 52:486-492.
7. Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S. 2008. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int. 28:1332-1343.
8. Ikeda M, et al. 2005. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem. Biophys. Res. Commun. 329:1350-1359. (Pubitemid 40568718)
9. Kong W, Engel K, Wang J. 2004. Mammalian nucleoside transporters. Curr. Drug Metab. 5:63-84. (Pubitemid 38279408)
10. Leung GP, Man RY, Tse CM. 2005. Effect of thiazolidinediones on equilibrative nucleoside transporter-1 in human aortic smooth muscle cells. Biochem. Pharmacol. 70:355-362. (Pubitemid 40905107)
11. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. 2005. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41:275-279. (Pubitemid 40165370)
12. Morello J, et al. 2010. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. J. Infect. Dis. 202:1185-1191.
13. Smee DF, Matthews TR. 1986. Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells. Antimicrob. Agents Chemother. 30:117-121. (Pubitemid 16097386)
14. Sun Y, Chung DH, Chu YK, Jonsson CB, Parker WB. 2007. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5′- triphosphate, not with inhibition of IMP dehydrogenase. Antimicrob. Agents Chemother. 51:84-88. (Pubitemid 46047691)
15. Tachibana-Iimori R, et al. 2004. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19:375-380.
16. Thomas E, et al. 2011. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53:32- 41.
17. Tsubota A, Hirose Y, Izumi N, Kumada H. 2003. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br. J. Clin. Pharmacol. 55:360-367. (Pubitemid 36535366)
18. Tsubota A, et al. 2011. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients. Liver Int. [Epub ahead of print.10.1111/ j.1478-3231.2011.02727.x.
19. Vickers MF, et al. 1999. Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q). Biochem. J. 339:21-32. (Pubitemid 29179286)
20. Ward JL, Sherali A, Mo ZP, Tse CM. 2000. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. J. Biol. Chem. 275:8375-8381.
21. Yamamoto T, et al. 2007. Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. Eur. J. Pharmacol. 557:1-8. (Pubitemid 46135552)
22. Yao SY, et al. 2002. Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. J. Biol. Chem. 277:24938-24948.